arrow
F

Francesco Di Costanzo

University of Florence
H指数:46
被引数:8,953

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

Antonuzzo, L.; Lavacchi, D.; Spada, F.; Marconcini, R.; Gelsomino, F.; Amoroso, V.; Cosso, F.; Pellegrini, E.; Scolari, F.; Sparano, C.; 等. 依维莫司作为晚期神经内分泌肿瘤的维持疗法:来自MAVERIC II期试验的结果. Oncologist 2026, 31, oyaf432. [Google Scholar] [CrossRef] [PubMed]

2026-03-010
PRE
MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
2023-10-010
OA
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
2021-09-01138
OAAI
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

免疫检查点抑制剂治疗期间的流感疫苗适应症: 一项多中心前瞻性观察研究 (INVIDIa-2)

2021-05-2016
OAAI
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
2021-03-058
PRE
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
2020-11-0210
OAAI
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

帕妥珠单抗联合曲妥珠单抗和紫杉烷一线治疗HER2-positive局部复发或转移性乳腺癌的初步安全性和有效性 (PERUSE)

2019-05-0189
OAAI
Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
2019-04-015
PREAI
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

评估Ramucirumab联合紫杉醇作为晚期HER-2阴性胃癌或胃食管交界癌患者的切换维持与继续一线化疗: ARMANI III期试验

2019-03-2912
OAAI
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study
2018-09-0118
OAAI